MountainTAP-30
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
- NCT07076121 ↗
- Active, not recruiting
- Bristol-Myers Squibb
- Focused
We haven't built an HCP commentary report on MountainTAP-30 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MountainTAP-30 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Navlimetostat; Gemcitabine; Nab-paclitaxel; Placebo
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Placebo comparator
- Arm D · Placebo comparator
- Arm E · Experimental
- Arm F · Placebo comparator
- Enrollment
- 470 (estimated)
- Primary outcomes
- Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)
- Overall Survival (OS)
- Sponsor
- Bristol-Myers Squibb
- Start
- Oct 23, 2025
- Primary completion
- May 3, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07076121 · updated Jun 3, 2026